EUCTR2018-001741-14-IT进行中（未招募）1 期
A phase I/II dose escalation study evaluating safety and activity of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-alfa2 gene in multiple myeloma patients with early relapse after intensive front line therapy - TEM-MM
OSPEDALE SAN RAFFAELE0 个研究点目标入组 3 人开始时间: 2019年6月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Multiple myeloma patients with early relapse after intensive front-line treatment and disease measurable by serum biomarkers that have obtained at least a VGPR after second-line salvage treatment;
- •2. Able and willing to provide written informed consent;
- •3. Able to comply with study protocol and procedures;
- •4. Male or Female;
- •5. Age 18-70 years;
- •6. Fit patients: Performance status scores: ECOG <2 and Karnofsky > 70%; Life expectancy of = 6 months;
- •7. Adequate cardiac, renal, hepatic and pulmonary functions;
- •8. Women of child-bearing potential enrolled in the study must have a negative pregnancy test at screening and agree to use acceptable methods of contraception during the trial;
- •9. Men enrolled in the study with partners who are women of child bearing potential, must be willing to use an acceptable barrier contraceptive method during the trial or have undergone successful vasectomy at least 6 months prior to entry into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. Use of other investigational agents within 4 weeks prior to experimental treatment (within 6 weeks if use of long-acting agents);
- •2. Severe active viral, bacterial, or fungal infection at eligibility evaluation;
- •3. Active autoimmune disease or a history of clinically relevant autoimmune manifestations requiring immunosuppressive treatment, i.e. psoriasis, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, immune-mediated peripheral neuropathies;
- •4. Sarcoidosis requiring active steroid or immunosuppressive treatment;
- •5. Primary amyloidosis;
- •6. History of neuropsychiatric illness including severe depression, schizophrenia, bipolar disorders, impaired cognitive function, dementia or suicidal tendency;
- •7. Neuropathy > grade 2;
- •8. History of severe cardiovascular disease such as prior stroke, coronary artery disease requiring intervention, unresolved arrhythmias;
- •9. Malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or family history of familial cancer syndromes;
- •10. Myelodysplasia, cytogenetic or molecular alterations specifically associated with clonal hematopoiesis of the myeloid lineage, or other serious hematological disorder other than the plasma cell dyscrasia;
- •11.Other clinical conditions judged by the Investigator non-compatible with the study procedures;
- •12. Positivity for HIV-1, HIV-2 (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA (or negative HCV RNA but on antiviral treatment) and/or Treponema Pallidum or Mycoplasma active infection;
- •13. Active alcohol or substance abuse within 6 months of the study;
- •14. Pregnancy or lactation;
- •15. Previous allogeneic bone marrow transplantation, kidney or liver transplant, or gene therapy;
- •16. Prior to conditioning: inability to meet the target mobilization cell number after at least 2 attempts of HSPC collection.
研究者
相似试验
已完成
1 期
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
尚未招募
不适用
GEN-001 multiple dose phase 1 studyKCT0006311Jeonbuk National University Hospital12
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2018-002146-37-ITINCYTE CORPORATIO18
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858EUCTR2018-002146-37-FRIncyte Corporation18